News
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: ...
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...
The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...
1d
Stocktwits on MSNThis Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity
Wells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s ...
Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.
One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...
After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...
Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...
Sarepta Therapeutics (NASDAQ:SRPT) has hired a lobbying firm with close ties to the Trump administration as regulatory ...
Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results